GlycoMimetics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for GlycoMimetics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	27.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

May 26

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year

May 12

GlycoMimetics EPS beats by $0.04

May 03

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Mar 26

GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares

Feb 19

GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings

Jan 24

How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?

Dec 28

New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease

Dec 07

Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Dec 07

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as GlycoMimetics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:GLYC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	0	-40	-35	-35	N/A
6/30/2024	0	-39	-36	-36	N/A
3/31/2024	0	-37	-34	-34	N/A
12/31/2023	0	-37	-35	-35	N/A
9/30/2023	N/A	-38	-35	-35	N/A
6/30/2023	N/A	-37	-35	-35	N/A
3/31/2023	0	-42	-44	-44	N/A
12/31/2022	0	-47	-47	-46	N/A
9/30/2022	0	-54	-51	-51	N/A
6/30/2022	0	-63	-60	-60	N/A
3/31/2022	0	-64	-57	-57	N/A
12/31/2021	1	-63	-58	-57	N/A
9/30/2021	1	-62	-54	-54	N/A
6/30/2021	2	-58	-49	-49	N/A
3/31/2021	2	-58	-50	-50	N/A
12/31/2020	10	-51	-39	-39	N/A
9/30/2020	10	-50	-42	-42	N/A
6/30/2020	9	-50	-44	-44	N/A
3/31/2020	9	-51	-41	-41	N/A
12/31/2019	N/A	-58	-52	-52	N/A
9/30/2019	N/A	-57	-49	-49	N/A
6/30/2019	N/A	-55	-46	-46	N/A
3/31/2019	N/A	-51	-48	-47	N/A
12/31/2018	N/A	-48	-43	-43	N/A
9/30/2018	N/A	-44	-42	-42	N/A
6/30/2018	N/A	-40	N/A	-38	N/A
3/31/2018	N/A	-37	N/A	-31	N/A
12/31/2017	N/A	-33	N/A	-30	N/A
9/30/2017	N/A	-32	N/A	-27	N/A
6/30/2017	0	-32	N/A	-29	N/A
3/31/2017	0	-32	N/A	-30	N/A
12/31/2016	0	-32	N/A	-30	N/A
9/30/2016	0	-32	N/A	-31	N/A
6/30/2016	0	-32	N/A	-10	N/A
3/31/2016	20	-13	N/A	-9	N/A
12/31/2015	20	-13	N/A	-8	N/A
9/30/2015	20	-11	N/A	-7	N/A
6/30/2015	20	-11	N/A	-26	N/A
3/31/2015	15	-13	N/A	-10	N/A
12/31/2014	15	-11	N/A	-4	N/A
9/30/2014	15	-8	N/A	-4	N/A
6/30/2014	15	-5	N/A	-2	N/A
3/31/2014	0	-16	N/A	-14	N/A
12/31/2013	4	-11	N/A	-16	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if GLYC's forecast earnings growth is above the savings rate (2.6%).

Earnings vs Market: Insufficient data to determine if GLYC's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if GLYC's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if GLYC's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GLYC's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if GLYC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/27 10:54
End of Day Share Price	2024/12/27 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GlycoMimetics, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ying Huang	Barclays
John Newman	Canaccord Genuity
Naureen Quibria	Capital One Securities, Inc.

GlycoMimetics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Price target decreased by 31% to US$5.50

No longer forecast to breakeven

Price target decreased by 35% to US$5.50

Forecast to breakeven in 2025

Price target decreased to US$8.50

Recent updates

GlycoMimetics, Inc. Provide Non-Compliance Update

Insufficient new directors

Crescent Biopharma, Inc. entered into an acquisition agreement to acquire GlycoMimetics, Inc. (NasdaqGM:GLYC) in a reverse merger transaction.

GlycoMimetics, Inc. Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Glycomimetics Announces to Reduce Its Workforce by Approximately 80%

We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate

GlycoMimetics Receives Non-Compliance letter from Nasdaq Regarding Listing Rule 5450(a)(1)

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

New major risk - Financial position

New major risk - Revenue and earnings growth

New minor risk - Profitability

No longer forecast to breakeven

GlycoMimetics, Inc. to Report Q1, 2024 Results on May 09, 2024

GlycoMimetics, Inc., Annual General Meeting, May 01, 2024

New minor risk - Profitability

GlycoMimetics Can Become A Game Changer In Blood Cancers

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

GlycoMimetics, Inc. to Report Q4, 2023 Results on Mar 27, 2024

Price target decreased by 31% to US$5.50

GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real

Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?

New minor risk - Share price stability

GlycoMimetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Senior VP & Chief Medical Officer recently bought US$90k worth of stock

GlycoMimetics, Inc. Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687

New minor risk - Market cap size

GlycoMimetics, Inc. Announces U.S. Food and Drug Administration Clears Addition of Time-Based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia

No longer forecast to breakeven

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

Price target decreased by 35% to US$5.50

Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?

Forecast to breakeven in 2025

Chief Medical Officer recently bought US$248k worth of stock

GlycoMimetics, Inc. Announces New Uproleselan Clinical Data in Both Frontline Unfit and Treated Secondary Acute Myeloid Leukemia presented at ASH Annual Meeting

Insider recently bought US$53k worth of stock

Insufficient new directors

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.34 loss in 3Q 2021)

Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely

GlycoMimetics, Inc. Appoints Edwin Rock as Chief Medical Officer

GlycoMimetics has a new Chief Medical Officer

Second quarter 2022 earnings released: US$0.25 loss per share (vs US$0.28 loss in 2Q 2021)

GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K

GlycoMimetics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$8.50

GlycoMimetics Receives a Notice from Nasdaq Regarding Minimum Bid Price Requirement

GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely

First quarter 2022 earnings released: US$0.28 loss per share (vs US$0.28 loss in 1Q 2021)

Insufficient new directors

GlycoMimetics, Inc. to Report Q1, 2022 Results on Apr 28, 2022

GlycoMimetics, Inc., Annual General Meeting, May 18, 2022

GlycoMimetics Positive Data For AML Therapy Increasingly Likely

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

GlycoMimetics, Inc. to Report Q4, 2021 Results on Mar 03, 2022

GlycoMimetics, Inc. Appoints Bruce Johnson as Senior Vice President and Chief Commercial Officer

Insufficient new directors

Insufficient new directors

Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation

Independent Director recently bought US$82k worth of stock

Price target increased to US$14.50

GlycoMimetics, Inc. Announces Efficacy and Safety Data from Phase 1/2 Clinical Study of Uproleselan Published in BLOOD

We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully

Price target increased to US$14.50

Trial Launches to Evaluate GlycoMimetics’ Uproleselan Added to Cladribine Plus Low-Dose Cytarabine in AML Patients

GlycoMimetics, Inc. Announces Initiation of Clinical Trial Evaluating Uproleselan in Combination with Venetoclax and Azacitidine

GlycoMimetics, Inc.(NasdaqGM:GLYC) dropped from Russell 3000E Value Index

Consensus forecasts updated

GlycoMimetics, Inc. Announces Investigator-Sponsored Phase 2 Clinical Trial Evaluating Uproleselan for Prevention of Gastro-Intestinal Toxicity in Autologous Hematopoietic Cell Transplantation

GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study

Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year